IMMUNOLOGIC EVALUATIONS OF HIV-INFECTED PREGNANT WOMEN ON HAART

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究将解决以下关于hiv感染孕妇免疫保存和/或重建的问题：1)hiv感染孕妇接受HAART治疗后的免疫反应是否与未感染孕妇有足够的差异，以证明对这组患者进行特殊免疫和/或其他预防策略是合理的？2)分娩后停止HAART治疗对感染艾滋病毒妇女的免疫反应有何影响？为了解决第一个问题，我们将比较40名接受HAART治疗的hiv感染孕妇与10名未感染孕妇之间的念珠菌特异性细胞介导免疫和对流感疫苗的反应。第二个问题将通过在怀孕期间和分娩后第一年测量艾滋病毒特异性和抗微生物免疫来解决。这两种比较的显著差异表明，在这种情况下不应停止HAART治疗，我们需要修改目前对感染艾滋病毒的孕妇的管理。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will address the following questions regarding immune preservation and/or reconstitution of HIV-infected pregnant women: 1) Do immune responses of HIV-infected pregnant women on HAART differ enough from those of uninfected pregnant women to justify special immunization and/or other prophylactic strategies for this group of patients? 2) What is the toll of stopping HAART after delivery on the immune responses of HIV-infected women? To address the first question, we will compare candida-specific cell-mediated immunity and responses to influenza vaccine among 40 HIV-infected pregnant women on HAART vs. 10 uninfected pregnant controls. The second question will be tackled by measuring HIV-specific and anti-microbial immunity during pregnancy and the first year after delivery. Significant differences in either of these comparisons will indicate that HAART should not be stopped in this setting and that we need to revise our current management of HIV-infected pregnant women.